Originally posted at http://www.iol.co.za/
September 26 2012, By Julie Steenhuysen

Chicago – In a new lead on Alzheimer’s research, Johnson & Johnson is bankrolling a three-year pilot study of people with Down syndrome to identify the early changes that herald dementia, which afflicts up to 75 percent of adults with the condition.

The aim is to generate support for a much bigger, public-private partnership funded by drugmakers, advocates and government agencies that will study at least 1,000 people with Down syndrome, tracking them from an early age and eventually testing treatments to keep dementia from developing.

Read the full story at http://www.iol.co.za/.